
Background Pulmonary hypertension (PH) is a progressive and debilitating condition with a high rate of mortality. Riociguat (BAY 63-2521) is a new drug in development for PH that is well tolerated [1,2] and has superior efficacy to nitric oxide in patients with PH [2]. Treatment recommendations for PH are based on combination therapies that include warfarin. The aim of this study was to investigate potential pharmacodynamic or pharmacokinetic interactions of riociguat and warfarin.
Pharmacology, Poster Presentation, Pharmacology (medical)
Pharmacology, Poster Presentation, Pharmacology (medical)
| citations This is an alternative to the "Influence" indicator, which also reflects the overall/total impact of an article in the research community at large, based on the underlying citation network (diachronically). | 3 | |
| popularity This indicator reflects the "current" impact/attention (the "hype") of an article in the research community at large, based on the underlying citation network. | Average | |
| influence This indicator reflects the overall/total impact of an article in the research community at large, based on the underlying citation network (diachronically). | Average | |
| impulse This indicator reflects the initial momentum of an article directly after its publication, based on the underlying citation network. | Average |
